Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

23.7K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
23.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of Cardiac Magnetic Resonance Imaging on Revascularization in Ischemic Left Ventricular Dysfunction.

Life (Basel, Switzerland)·2026
Same author

Sirt1 transgene delivery improves diabetes-impaired wound healing.

Bioactive materials·2026
Same author

Spatial CRISPR screens map total RNA in tissue.

Nature biotechnology·2026
Same author

Biphasic modulation of hen egg white lysozyme amyloid aggregation by dioctyl sulfosuccinate sodium: Effects of cosolutes.

International journal of biological macromolecules·2026
Same author

How is agentic AI changing how we do science?

Cell systems·2026
Same author

Biophysical characterization of an engineered recombinant Zeocin Binding Protein (ZBP) mutant.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026

Related Experiment Video

Updated: Jul 9, 2025

An In Vitro 3D Model and Computational Pipeline to Quantify the Vasculogenic Potential of iPSC-Derived Endothelial Progenitors
06:36

An In Vitro 3D Model and Computational Pipeline to Quantify the Vasculogenic Potential of iPSC-Derived Endothelial Progenitors

Published on: May 13, 2019

6.1K

Modeling diabetic endothelial dysfunction with patient-specific induced pluripotent stem cells.

Rayyan Gorashi1,2, Nancy Rivera-Bolanos1,2, Caitlyn Dang3

  • 1Department of Biomedical Engineering Northwestern University Evanston and Chicago Illinois USA.

Bioengineering & Translational Medicine
|November 29, 2023
PubMed
Summary

Human stem cell-derived endothelial cells model diabetic dysfunction, revealing genetic and environmental factors. This approach identified potential drug treatments for personalized cardiovascular care in diabetes.

Keywords:
cardiovascular diseasesdiabetes mellitusdisease modelingdrug screeningendothelial cellsinduced pluripotent stem cells

More Related Videos

Directed Differentiation of Hemogenic Endothelial Cells from Human Pluripotent Stem Cells
04:23

Directed Differentiation of Hemogenic Endothelial Cells from Human Pluripotent Stem Cells

Published on: March 31, 2021

2.2K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

2.9K

Related Experiment Videos

Last Updated: Jul 9, 2025

An In Vitro 3D Model and Computational Pipeline to Quantify the Vasculogenic Potential of iPSC-Derived Endothelial Progenitors
06:36

An In Vitro 3D Model and Computational Pipeline to Quantify the Vasculogenic Potential of iPSC-Derived Endothelial Progenitors

Published on: May 13, 2019

6.1K
Directed Differentiation of Hemogenic Endothelial Cells from Human Pluripotent Stem Cells
04:23

Directed Differentiation of Hemogenic Endothelial Cells from Human Pluripotent Stem Cells

Published on: March 31, 2021

2.2K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

2.9K

Area of Science:

  • Cardiovascular Biology
  • Metabolic Disorders
  • Stem Cell Biology

Background:

  • Diabetes mellitus significantly increases cardiovascular disease risk, primarily through endothelial dysfunction.
  • Existing in vitro models struggle to capture the complex interplay of genetic and environmental factors in diabetic endothelial dysfunction.
  • Human induced pluripotent stem cell (iPSC)-derived endothelial cells (ECs) offer a promising avenue for developing more comprehensive disease models.

Purpose of the Study:

  • To develop and validate in vitro models of diabetic endothelial dysfunction using patient-derived and healthy iPSC-ECs.
  • To investigate the impact of genetic background and diabetogenic environmental factors on endothelial cell function.
  • To utilize these models for screening potential therapeutic agents for diabetic cardiovascular complications.

Main Methods:

  • Generation of endothelial cells from human iPSC lines from diabetic patients and healthy controls.
  • Culture of iPSC-ECs under standard and diabetogenic mimicking conditions.
  • Transcriptome-wide RNA sequencing (RNA-seq) to analyze gene expression profiles.
  • In vitro screening of angiotensin receptor blockers (ARBs) for therapeutic efficacy.

Main Results:

  • Diabetic patient-derived iPSC-ECs exhibited a recapitulated diabetic phenotype, independent of the culture environment.
  • Exposure to diabetogenic conditions induced dysfunction in healthy iPSC-ECs but did not alter already dysfunctional diabetic iPSC-ECs.
  • RNA-seq identified significant transcriptome-wide differences between healthy and diabetic iPSC-ECs.
  • The iPSC-based models successfully identified patient-specific ARBs that improved endothelial function in vitro.

Conclusions:

  • iPSC-derived endothelial cells provide robust in vitro models for studying diabetic endothelial dysfunction, incorporating genetic and environmental influences.
  • These models offer valuable insights into the pathophysiology of diabetes-related cardiovascular complications.
  • iPSC technology holds significant potential for personalized medicine and accelerated drug discovery in diabetes treatment.